fbpx
October 28, 2022

NIH to Test Pfizer’s Paxlovid for Long COVID NIH to Test Pfizer’s Paxlovid for Long COVID

CHICAGO (Reuters) – The U.S. National Institutes of Health’s $1 billion RECOVER Initiative has picked Pfizer Inc’s antiviral drug Paxlovid as the first treatment it will […]
October 28, 2022

Gilead Profit Tops Expectations Despite Lower COVID Drug Sales, Outlook Raised Gilead Profit Tops Expectations Despite Lower COVID Drug Sales, Outlook Raised

(Reuters) – Gilead Sciences Inc on Thursday posted a higher-than-expected third-quarter profit on the back of strong demand for its HIV and cancer drugs, which helped […]
October 28, 2022

‘Reassuring Data’ for Two Multiple Sclerosis Meds in Pregnancy ‘Reassuring Data’ for Two Multiple Sclerosis Meds in Pregnancy

Continuing treatment with two common multiple sclerosis (MS) medications during pregnancy is associated with significantly lower relapse rates and few pregnancy-related complications, new research shows. Results […]
October 28, 2022

A Better Way to Predict Fall Risk in Patients With MS? A Better Way to Predict Fall Risk in Patients With MS?

Falls are common in patients with multiple sclerosis (MS) and a new study suggests impairment in a specific aspect of neuromuscular function can identify those at […]
October 28, 2022

Is pCR a Reliable Survival Surrogate in Breast Cancer Trials? Is pCR a Reliable Survival Surrogate in Breast Cancer Trials?

Pathologic complete response (pCR) is not a reliable surrogate endpoint in trials evaluating neoadjuvant therapies for early breast cancer, according to a critical analysis of the […]
October 28, 2022

Cancer Deaths Fall; Women’s Weight Loss; and Palliative Sedation Cancer Deaths Fall; Women’s Weight Loss; and Palliative Sedation

Cancer Deaths Fall in the US Cancer deaths continued to fall in the US, a new report shows. Total cancer deaths fell 2.1% per year from […]
October 27, 2022

RBX2660 Shows Promise in Breaking the Cycle of Recurrent C diff RBX2660 Shows Promise in Breaking the Cycle of Recurrent C diff

CHARLOTTE, N.C. — RBX2660 could be a new option for people who experience recurrent, debilitating Clostridioides difficile infections. Following a standard course of antibiotics, a one-time […]
October 27, 2022

Oregon Could Be First State to Make Healthcare a Human Right Oregon Could Be First State to Make Healthcare a Human Right

SALEM, Ore. (AP) — Oregon voters are being asked to decide whether the state should be the first in the nation to amend its constitution to […]
October 27, 2022

DTC Telemedicine Expands Access to Gender-Affirming Therapy DTC Telemedicine Expands Access to Gender-Affirming Therapy

Direct-to-consumer telemedicine services that provide gender-affirming hormone therapy appear to follow evidence-based guidelines and charge about the same as brick-and-mortar medical centers, according to researchers who […]
Prev page
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448449450451452453454455456457458459460461462463464465466467468469470471472473474475476477478479480481482483484485486487488489490491492493494495496497498499500501502503504505506507508509510511512513514515516517518519520521522523524525526527528529530531532533534535536537538539540541542543544545546547548549550551552553554555556557558559560561562563564565566567568569570571572573574575576577578579580581582583584585586587588589590591592593594595596597598599600601602603604605606607608609610611612613614615616617618619620621622623624625626627628629630631632633634635636637638639640641642643644645646647648649650651652653654655656657658659660661662663664665666667668669670671672673674675676677678679680681682683684685686687688689690691692693694695696697698699700701702703704705706707708709710711712713714715716717718719720721722723724725726727728729730731732733734735736737738739740741742743744745746747748749750751752753754755756757758759760761762763764765766767768769770771772773774775776777778779780781782783784785786787788789790791792793794795796797798799800801802803804
Next page
google.com, pub-5711488453051849, DIRECT, f08c47fec0942fa0